Filing Flows › Johnson & Johnson (JNJ) › Innovative Medicine revenue
Johnson & Johnson (JNJ) Innovative Medicine revenue by quarter
Johnson & Johnson's Innovative Medicine revenue was $16.8B in Q3 2026 (third quarter 2026), +2% from Q2 2026. Over the last 7 quarters it ranged from $13.9B (Q1 2025) to $16.8B (Q3 2026).
| Quarter | Innovative Medicine revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $16.8B | +2% | +8% |
| Q2 2026 | $16.4B | +6% | +8% |
| Q1 2026 | $15.4B | -2% | +11% |
| Q4 2025 | $15.8B | +1% | — |
| Q3 2025 | $15.6B | +2% | — |
| Q2 2025 | $15.2B | +10% | — |
| Q1 2025 | $13.9B | — | — |
Q3 2026 at a glance
Johnson & Johnson, Q3 2026: revenue $25.4B (+6% year over year), operating margin 0.1%, net earnings $210M, operating cash flow $7.7B. The chart follows the revenue to costs, profit and cash.
Questions
What is Johnson & Johnson's Innovative Medicine revenue?
Johnson & Johnson's Innovative Medicine revenue was $16.8B in Q3 2026 (third quarter 2026), +2% from Q2 2026.
How has Johnson & Johnson's Innovative Medicine revenue changed?
Over the last 7 quarters it ranged from $13.9B (Q1 2025) to $16.8B (Q3 2026).